Renal Replacement Therapy

Publisher Website
Google Scholar
Abstract
Each year in the United States end-stage renal disease develops in almost one person per 10,000 population. Patients with this disease must select a therapy to survive. Such patients have a variety of treatments from which to choose: in-center or home hemodialysis, intermittent peritoneal dialysis at home, continuous ambulatory peritoneal dialysis, and transplantation from a cadaveric or living related donor. The possibility of a randomized prospective comparison of these treatments seems unlikely, since after receiving a full explanation of the alternatives, few patients would allow their choice to be determined randomly. We must, then, make do with nonprospective, nonrandomized comparisons, . . .